Gilead Sciences Completes Tubulis Acquisition for up to $5bn
Gilead Sciences has completed its acquisition of German biotech Tubulis for up to $5 bn, paying $3.15 bn upfront with up to $1.85 bn in milestones. The deal gives Gilead access to Tubulis’ ADC platform and pipeline, including TUB‑040 and TUB‑030, strengthening its oncology portfolio.
Mentari Therapeutics to Go Public via $421M Reverse Merger with InMed, Raising $290M Private Placement
Mentari Therapeutics announced a reverse merger with public shell InMed Pharmaceuticals, creating a combined company under the Mentari name with a pro forma equity value of about $421 million. The transaction includes a concurrent private placement raising roughly $290 million,...
Zydus Lifesciences to Acquire Assertio Holdings for $166.4M in All‑cash Deal
Zydus Lifesciences announced it will acquire US oncology drugmaker Assertio Holdings Inc. for $166.4 million in an all‑cash tender offer. The transaction, structured as a tender offer followed by a merger, will give Zydus a specialty oncology commercial platform in the...
Pfizer and Arvinas Sell Breast Cancer Drug Rights to Rigel for $35M
Pfizer and its partner Arvinas have sold the rights to their recently approved breast cancer drug to Rigel Pharmaceuticals for $35 million, a steep drop from the $1 billion invested in development.
Bristol Myers Squibb Signs $15.2B Licensing Deal with China's Hengrui Pharma
On May 12, 2026, Bristol Myers Squibb announced a global strategic collaboration with Hengrui Pharma to license 13 early‑stage oncology, hematology and immunology assets. The deal includes $600 million upfront and up to $15.2 billion in total value, granting BMS exclusive ex‑China...
Scarlet Therapeutics Raises £3.2M Seed Round to Advance Lab‑grown Red Blood Cell Therapies
Scarlet Therapeutics, a UK biotech developing lab‑grown red blood cell therapies, announced a seed round of £3.2 million (≈$4.1 million) led by Eos Advisory, with participation from Oshen Bio, Daft Capital and existing backer SCVC. The funding will support pre‑clinical studies, animal...
Angelini Pharma Agrees to Acquire Catalyst Pharma for up to $4.1B
Italy's Angelini Pharma announced it will acquire US‑listed Catalyst Pharma for up to $4.1 billion, paying $31.50 per share (a 28% premium). The acquisition gives Angelini three FDA‑approved neuromuscular and epilepsy products and marks its entry into the US market. The...
MSD Completes $5.3B Acquisition of Terns Pharmaceuticals
Merck & Co (MSD) completed its acquisition of Terns Pharmaceuticals, buying all outstanding shares at $53 per share for roughly $5.3 billion, making Terns a wholly‑owned subsidiary and expanding MSD’s chronic myeloid leukaemia pipeline. The cash tender offer closed after the...
Nuvation Bio Acquires Exclusive Rights to Safusitinib in Japan From Daiichi Sankyo
Nuvation Bio announced that it has completed the acquisition of exclusive rights to the IDH1‑mutant glioma drug safusitinib in Japan from partner Daiichi Sankyo. The agreement, finalized in April 2026, expands Nuvation’s portfolio and enables the company to advance the...
UCB to Acquire Candid Therapeutics for up to $2.2 Billion
UCB announced a definitive agreement to acquire Candid Therapeutics, a clinical‑stage biotech, for up to $2.2 billion, comprising $2 billion in cash upfront and up to $200 million in milestones. The acquisition expands UCB’s T‑cell engager pipeline and is expected to close by...
AbbVie to Fund Kestrel Therapeutics with up to $1.45B in Strategic Agreement, Includes Option to Acquire
Kestrel Therapeutics has signed a strategic agreement with AbbVie that provides up to $1.45 billion in funding for its pan‑KRAS inhibitor program. The deal includes an exclusive option for AbbVie to acquire Kestrel upon achievement of development and regulatory milestones.
Chiesi Group to Acquire KalVista Pharmaceuticals for $1.9B
Chiesi Group announced a $1.9 billion cash acquisition of KalVista Pharmaceuticals, paying $27 per share, a 40.3% premium. The deal adds KalVista's oral HAE drug Ekterly to Chiesi's rare-disease portfolio and is expected to close in the third quarter of...
Teva to Acquire Emalex Biosciences for $900 Million
Teva Pharmaceutical Industries announced it will acquire Emalex Biosciences for $900 million, including a $700 million upfront payment and up to $200 million in milestones, to add the late‑stage pediatric Tourette syndrome candidate Ecopipam to its pipeline. The transaction is expected to close...
AbbVie Secures Option to Acquire Kestrel Therapeutics for Up to $1.45B
AbbVie announced an exclusive right to acquire Kestrel Therapeutics, valued at up to $1.45 billion, contingent on Kestrel meeting development and regulatory milestones for its oral pan‑KRAS inhibitor KST‑6051. The agreement includes AbbVie funding the program and gives it the option...
Ligand Pharmaceuticals Acquires XOMA for $739 Million
Ligand Pharmaceuticals announced a $739 million acquisition of XOMA, aiming to expand its royalty revenue base and add late‑stage and commercial assets to its portfolio. The deal reflects ongoing consolidation in the biopharma sector among royalty‑financing, asset‑light companies. The transaction was...